Boston Scientific Corporation $BSX Shares Purchased by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its stake in Boston Scientific Corporation by 8.2%, holding 2,834,977 shares worth approximately $283.95 million, making it the firm's 23rd largest investment.
• Boston Scientific reported quarterly earnings of $0.75 per share, exceeding expectations of $0.72, with revenue hitting $5.06 billion, a 22.8% increase from the previous year.
• Insider trading activity shows both Director Yoshiaki Fujimori and CEO Michael F. Mahoney significantly reduced their shareholdings, with the CEO selling over 164,000 shares for approximately $17 million.

Aberdeen Group plc grew its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,834,977 shares of the medical equipment provider's stock after acquiring an additional 213,753 shares during the quarter. Boston Scientific comprises about 0.6% of Aberdeen Group plc's portfolio, making the stock its 23rd largest position. Aberdeen Group plc owned 0.19% of Boston Scientific worth $283,951,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the stock. Colonial Trust Co SC increased its position in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV acquired a new stake in Boston Scientific in the 4th quarter worth approximately $25,000. Sunbeam Capital Management LLC acquired a new stake in Boston Scientific in the 4th quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the 1st quarter worth approximately $27,000. Finally, Ameriflex Group Inc. purchased a new position in Boston Scientific during the 4th quarter worth approximately $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total value of $17,051,094.67. Following the sale, the chief executive officer directly owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock worth $35,976,603 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

NYSE:BSX traded up $0.5940 during trading hours on Tuesday, hitting $103.6440. The company's stock had a trading volume of 4,612,498 shares, compared to its average volume of 7,564,196. Boston Scientific Corporation has a 52-week low of $78.08 and a 52-week high of $108.94. The company has a market capitalization of $153.57 billion, a PE ratio of 61.69, a PEG ratio of 2.48 and a beta of 0.66. The business's 50-day moving average is $103.62 and its two-hundred day moving average is $102.09. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter last year, the business posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Morgan Stanley lifted their price objective on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Robert W. Baird upped their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Finally, UBS Group upped their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and a consensus target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.